Perilesional heberferon in the treatment of basal cell carcinoma of high risk
Keywords:
heberferón, basal carcinomaAbstract
The HeberFERON is a formulation that contains a synergetic combination of interferons alpha 2b and gamma, with anti-proliferative, immune modulating, anti-angiogenic and antitumoral properties. The basal carcinoma (CBC) is the most common type of skin cancer. It is considered like a locally invasive, aggressive and destructive malignant tumor, but rarely metastasize. We report the case of a patient with recurrent Basal Carcinoma located in nasal right wing, of 4 centimeters and loss of the cartilage, in which the conventional surgery had been practiced.
Objective: Reporting the case of a patient with high-risk CBC previously treated by surgical way 8 years ago, that shows tumoral recidive in similar place, nasal right wing.
Case presentation: Feminine patient, phototype III, of 69 years of age, operated on in the 2008 due to a tumoral lesion of 5 millimeters in nasal right wing, the histological study evidenced a nodular pigmented CBC that compromised its reticular dermis, with the tumor inside the borders of section surgical, they did not report if in the studied sample perineural invasion was found.
The lesion reappears in the term of a year and when we evaluate the patient in April of 2016 we found, to the physical examination, a 4-centimeter lesion frankly nodular, infiltrated and lobed, with loss of the nasal cartilage. A dermatoscopy study that showed an image in maple leaf, in wheel of carts, arboriform vessels, as well as points and globules that suggest nests of basaloid cells.
The patient refuses to a re-intervention and to be about a lesion in right nasal wing recurrent, we propose perilesional treatment with Heberferón 3,5 million three times per week, during three weeks with 9 administrations’ total if it was confirmed, with a histological reassessment, the presence of a CBC and if when carrying on studies of blood chemistry and in the case history, the patient fulfilled the criteria established according to protocol for the administration of the product.
Operated in the 2004 to present Duct Carcinoma of left breast, performing a cuandrantectomy and Radiation Therapy.
Downloads
Published
How to Cite
Issue
Section
License
Los autores conservan los derechos de autor y todos los derechos de publicación sin restricciones.
Investigaciones Medicoquirúrgicas se encuentra sujeta bajo la Licencia Creative Commons Atribución-No Comercial 4.0 Internacional (CC BY-NC 4.0) y sigue el modelo de publicación de SciELO Publishing Schema (SciELO PS) para la publicación en formato XML.
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y construir a partir del material.
La licencia no puede revocar estas libertades en tanto usted siga los términos de la licencia
Bajo los siguientes términos:
- Atribución — Usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
- No Comercial — Usted no puede hacer uso del material con propósitos comerciales.
- No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
- No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
- No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
